An optimized lentiviral vector corrects efficiently the human sickle cell disease phenotype by Weber, Leslie et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.omtm.2018.07.012
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Weber, L., Poletti, V., Magrin, E., Antoniani, C., Martin, S., Bayard, C., ... Miccio, A. (2018). An optimized
lentiviral vector corrects efficiently the human sickle cell disease phenotype. Molecular Therapy - Methods and
Clinical Development. https://doi.org/10.1016/j.omtm.2018.07.012
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 29. Jul. 2020
Accepted Manuscript
An optimized lentiviral vector corrects efficiently the human sickle cell disease
phenotype
Leslie Weber, Valentina Poletti, Elisa Magrin, Chiara Antoniani, Samia Martin,
Charles Bayard, Hanem Sadek, Tristan Felix, Vasco Meneghini, Michael N. Antoniou,
Wassim El- Nemer, Fulvio Mavilio, Marina Cavazzana, Isabelle Andre-Schmutz,
Annarita Miccio
PII: S2329-0501(18)30076-7
DOI: 10.1016/j.omtm.2018.07.012
Reference: OMTM 167
To appear in: Molecular Therapy: Methods & Clinical Development
Received Date: 26 June 2018
Accepted Date: 29 July 2018
Please cite this article as: Weber L, Poletti V, Magrin E, Antoniani C, Martin S, Bayard C, Sadek H,
Felix T, Meneghini V, Antoniou MN, El- Nemer W, Mavilio F, Cavazzana M, Andre-Schmutz I, Miccio
A, An optimized lentiviral vector corrects efficiently the human sickle cell disease phenotype, Molecular
Therapy: Methods & Clinical Development (2018), doi: 10.1016/j.omtm.2018.07.012.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1
 An optimized lentiviral vector corrects efficiently the human sickle cell disease phenotype 
 
Leslie Weber1,2, Valentina Poletti3, Elisa Magrin4, Chiara Antoniani5,6, Samia Martin3, 
Charles Bayard1, Hanem Sadek1, Tristan Felix5,6, Vasco Meneghini5,6, Michael N Antoniou7, 
Wassim El- Nemer8,9,10, Fulvio Mavilio5,11, Marina Cavazzana1,4,5, Isabelle Andre-Schmutz1,5 
and Annarita Miccio3,5,6 
 
1Laboratory of Human Lymphohematopoiesis, INSERM UMR_S1163, 75015 Paris, France 
2Paris Diderot University – Sorbonne Paris Cité, 75015 Paris, France 
3Genethon, INSERM UMR951, 91000 Evry, France 
4Biotherapy Department, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris, 
75015 Paris, France 
5Paris Descartes–Sorbonne Paris Cité University, Imagine Institute, 75015 Paris, France 
6Laboratory of chromatin and gene regulation during development, INSERM UMR_S1163, 
75015 Paris, France 
7King’s College London, WC2R 2LS London, England  
8Biologie Intégrée du Globule Rouge, INSERM UMR_S1134, Paris Diderot University, 
Sorbonne Paris Cité, Univ. de la Réunion, Univ. des Antilles, 75015 Paris, France 
9Institut National de la Transfusion Sanguine, 75015 Paris, France 
10Laboratoire d’Excellence GR-Ex, 75015 Paris, France 
11Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, 
Italy 
Correspondence should be addressed to A.M., Imagine Institute, 24, Boulevard du 
Montparnasse, 75015 Paris, France. E-mail address: annarita.miccio@institutimagine.org.  
Running title: Lentiviral-based gene therapy for Sickle Cell Disease  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
ABSTRACT 
 
 
Autologous transplantation of hematopoietic stem cells transduced with a lentiviral vector 
(LV) expressing an anti-sickling HBB variant is a potential treatment for sickle cell disease 
(SCD). With a clinical trial as our ultimate goal, we generated LV constructs containing an 
anti-sickling HBB transgene (HBBAS3), a minimal HBB promoter and different combinations 
of DNase I hypersensitive sites (HSs) from the locus control region (LCR). Hematopoietic 
stem progenitor cells (HSPCs) from SCD patients were transduced with LVs containing 
either HS2 and HS3 (β-AS3) or HS2, HS3 and HS4 (β-AS3 HS4). The inclusion of the HS4 
element drastically reduced vector titer and infectivity in HSPCs, with negligible 
improvement of transgene expression. Conversely, the LV containing only HS2 and HS3 was 
able to efficiently transduce SCD bone marrow and Plerixafor-mobilized HSPCs, with anti-
sickling HBB representing up to ~60% of the total HBB-like chains. The expression of the 
anti-sickling HBB and the reduced incorporation of the βS-chain in hemoglobin tetramers 
allowed up to 50% reduction in the frequency of RBC sickling under hypoxic conditions. 
Together these results demonstrate the ability of a high titer LV to express elevated levels of 
a potent anti-sickling HBB transgene ameliorating the SCD cell phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3
INTRODUCTION 
 
Sickle cell disease (SCD) is a severe genetic disorder affecting ~312,000 newborns 
worldwide annually.1 A single point mutation in the adult β-globin (HBB) gene causes a 
Glu>Val amino acid substitution in the β-globin chain (βS-globin). The sickle hemoglobin 
(HbS, α2βS2) has the propensity to polymerize under deoxygenated conditions, resulting in the 
production of sickle-shaped red blood cells (RBCs) that can cause occlusions of blood 
vessels, leading to impaired oxygen delivery to tissues, respiratory complications, organ 
damage and early mortality. Additionally, sickled RBCs are prone to hemolysis, thus the 
clinical phenotype is also characterized by hemolytic anemia. Current treatments include life-
long RBC transfusions and hydroxyurea, a drug that increases fetal Hb (HbF, α2γ2) 
synthesis2. Indeed, the clinical course of SCD is improved when fetal HBG genes are highly 
expressed, as seen in patients with naturally occurring mutations leading to hereditary 
persistence of fetal hemoglobin (HPFH). In SCD, HBG exerts a potent anti-sickling function 
by competing with the sickle βS-globin for incorporation in Hb tetramers and by inhibiting 
HbS polymerization. However, pharmacological treatments increasing HbF levels are not 
equally effective in all patients.2  
The only definitive cure for SCD patients is allogenic hematopoietic stem cell (HSC) 
transplantation. However, HSC transplantation from an HLA-matched related donor is 
available only to a fraction of patients.3 Transplantation of HSCs from matched unrelated 
donors are associated with a higher risk of graft-versus-host-disease, transplant rejection and 
infections3. With the advent of HBB expressing lentiviral vectors (LVs), transplantation of 
genetically modified autologous HSCs holds promise of circumventing the need for suitable 
donors and the morbidity and mortality associated with allogenic transplantation.  
LV-based ex vivo gene therapy strategies require the stable transfer of an anti-sickling 
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HBB globin transgene in the patient’s long-term repopulating HSCs and high, sustained and 
regulated expression of the therapeutic globin chain in their erythroid progeny. Several LVs 
have been developed and tested in murine models of SCD and patient hematopoietic stem 
progenitor cells (HSPCs).4-6 In these vectors, an anti-sickling HBB transgene (HBG or βT87Q 
and βAS3 HBB anti-sickling variants) is placed under the transcriptional control of the HBB 
promoter and key regulatory elements from the 16-kb human β-locus control region (βLCR), 
which is essential for high and regulated expression of the endogenous HBB gene family.7 
Since LVs cannot accommodate the entire LCR, only the 3 most transcriptionally potent out 
of the 5 DNase I hypersensitive sites (HS2, HS3 and HS4) were selected and reduced in size 
to fit into the vector packaging capacity. The combination of minimal core elements of HS2, 
HS3 and HS4 (each of them 0.2 to 0.4 kb-long) was associated with low transgene expression 
levels, positional variegation and transcriptional silencing, whereas extended HSs sustained 
high HBB-like globin expression.8, 9 Sequences flanking the HS core elements might indeed 
be required for synergistic activation of HBB-like globin gene expression.10 Therefore, HBB 
globin expressing LVs are exceptionally large, harboring a 2.6- to 3.4-kb “mini-LCR” 
containing extended HS2, HS3 and HS4.4-6 The large size of these vectors makes their 
production challenging and might affect gene transfer efficiency, particularly in HSPCs.8 
There have been three clinical trials for SCD using LVs expressing an anti-sickling 
HBB-like globin gene (see 11, 12). The first SCD patient to have undergone gene therapy 
showed a good correction of the clinical phenotype and the biological hallmarks of SCD.13 
However, in a parallel study using the same LV, gene marking in the peripheral blood was 
low in all treated SCD subjects, with no evidence of clinical benefit.14 Therefore, the 
development of high-titer LVs able to transduce a good proportion of HSCs and drive high 
levels of HBB-like expression is still a critical issue to achieve therapeutic efficacy in SCD 
patients. In particular, the choice of βLCR regulatory elements able to drive high levels of 
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HBB-like expression without compromising the vector titer is critical. 
Here, we show that a compact, high titer LV, containing only the HS2 and HS3 βLCR 
elements, is highly efficient in transducing a large proportion of SCD HSPCs derived from 
bone marrow or mobilized in the peripheral blood of SCD patients, and expressed therapeutic 
levels of a potent anti-sickling HBB transgene.  
 
RESULTS 
 
Design and characterization of lentiviral vectors expressing an anti-sickling human 
HBB transgene 
 
We generated two LVs carrying an anti-sickling human HBB transgene (HBBAS3) under the 
transcriptional control of a minimal HBB promoter and either two or three HSs from the 
human βLCR: HS2 and HS3 (β-AS3 LV) and HS2, HS3 and HS4 (β-AS3 HS4 LV)) (Figure 
1A). The HBBAS3 gene contains three mutations15 causing three potentially beneficial “anti-
sickling” amino-acidic substitutions (G16D, E22A, T87Q) in the LV-derived HBB chain 
(βAS3): A22 and Q87 impair respectively the axial and lateral contacts necessary for the 
formation of HbS polymers, and D16 increases the affinity to HBA chains, thus conferring to 
β
AS3
 a competitive advantage for the incorporation in the Hb tetramers15 (Figure 1A).  
VSV-G pseudotyped, third generation LVs were produced by standard transient 
transfection of HEK293T cells and concentrated by ultra-centrifugation. The physical titer of 
the two vectors, determined by measuring the viral p24 protein, was similar, indicating that a 
comparable amount of total viral particles was present in the β-AS3 LV and β-AS3 HS4 
vector preparations (Figure 1B). We then transduced HCT116 cells and human erythroid 
(HEL and K562) cell lines to determine the infectious titer by measuring the average number 
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of vector copies integrated per genome (vector copy number; VCN). The infectious titer of β-
AS3 LV was ~8-fold higher, compared to β-AS3 HS4 LV (Figure 1B). As a consequence, β-
AS3 LV showed a markedly increased infectivity, measured as ratio between the infectious 
and the physical titer (Figure 1B). We then transduced human G-CSF-mobilized peripheral 
blood (mPB) HSPCs from healthy donors (HD) with increasing amounts of vector 
preparations. Notably, β-AS3 LV showed a superior gene transfer efficiency compared to β-
AS3 HS4, leading to up to 2.40±0.58 vector copies per cell at the highest vector dose (Figure 
1C). 
Given these results, we next investigated the potential detrimental effects of the HS4 
element on viral titer and infectivity. Total RNA was extracted from HEK293T packaging 
cells transfected with β-AS3 and β-AS3 HS4 transfer vectors and LV packaging plasmids. 
RT-qPCR analysis revealed that the total viral genomic RNA containing the ψ+ packaging 
signal was significantly higher for β-AS3 LV compared to the HS4-containing LV (Figure 
1D). In addition, by using 3’ RACE-PCR, followed by Sanger sequencing, we detected a 
truncated β-AS3 HS4 viral genomic transcript (Figure S1A). We identified a canonical poly-
adenylation signal (AATAAA) in the HS4 element, likely responsible of the premature 
truncation of the β-AS3 HS4 viral transcripts (Figure S1A). However, RT-qPCR showed a 
comparable fraction of full length viral RNA (~20% of the total ψ+ viral genomic RNA) for 
both β-AS3 and β-AS3 HS4 LVs (Figure S1B). 
To understand the reasons for the significant drop in titer cause by the 1.1-kb long HS4, we 
constructed the β-AS3 HS4 core LV harboring a short 304-bp HS4 fragment containing the 
core HS4 element10 and lacking the polyadenylation site mapped in the long HS4 element. 
(Figure S1C). Although the shortening of the HS4 element restored most of the total  ψ+ viral 
genomic RNA levels, it did not increase significantly the infectious titer and infectivity in 
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HCT116 cells, thus indicating that even the core HS4 element contain sequences that are 
detrimental to the vector performance (Figure S1D and E). 
 
β-AS3 transduction leads to highly efficient gene transfer in SCD bone marrow HSPC 
 
In order to evaluate gene transfer efficiency of the β-AS3 and β-AS3 HS4 LVs, we 
transduced SCD patient bone marrow (BM) HSPCs samples with an equal number of 
infecting particles (multiplicity of infection [MOI] 4 to 360; n=2-6; 2 donors). HSPCs were 
either differentiated in liquid culture towards the erythroid lineage or plated in semi-solid 
medium containing cytokines supporting the clonal growth and differentiation of erythroid 
(BFU-E) and granulocyte-monocyte (CFU-GM) progenitors (Colony Forming Cell (CFC) 
assay). Lentiviral transduction did not affect erythroid proliferation and differentiation, and 
clonogenic potential of transduced HSPCs (Figure S2, Figure 2A and data not shown).  
Negligible gene transfer efficiency was observed using β-AS3 HS4 with a MOI lower 
than 36 (data not shown). HSPC transduction with β-AS3 HS4 at an MOI of 36 led to the 
integration of 0.55±0.41, 0.70±0.31 and 0.43±0.23 vector copies per cell in erythroblasts, and 
pools of BFU-E and CFU-GM, respectively. A 10-fold increase in β-AS3 HS4 infecting 
particles did not increase the gene transfer efficiency (Figure 2B). In contrast, β-AS3 was 
able to transduce HSPCs even at low MOIs (4- and 12; Figure 2B). The VCN of β-AS3 was 
positively correlated with the MOIs, rising up to 4.81±1.29 in erythroblasts, 4.13±0.95 in 
BFU-E and 1.49±0.67 in CFU-GM at an MOI of 360. Notably, at the same MOIs β-AS3 
transduction efficiency was significantly higher, as compared to β-AS3 HS4 (Figure 2B).  
To assess precisely the frequency of transduced HSPCs, we measured the gene 
transfer efficiency in individual BFU-E and CFU-GM (n=3-6; 2 donors). When HSPCs were 
transduced using the same vector doses, a higher proportion of transduced CFCs was 
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observed for β-AS3 compared to β-AS3 HS4 (Figure 2C). We observed up to 82% and 67% 
of β-AS3-transduced BFU-E and CFU-GM, respectively. In contrast, β-AS3 HS4 did not 
transduce >~40% of CFCs (Figure 2C). Samples containing <40% of transduced CFCs (e.g. 
β-AS3 HS4 MOI 360 and 36 and β-AS3 MOI 4 and 12) displayed a similar VCN 
distribution, with most of the transduced BFU-E and CFU-GM harboring 1 to 2 vector copies 
per genome. Notably, the high frequency of transduction reached using β-AS3 at the highest 
doses (e.g. MOI 36 and 360) was accompanied with a significantly higher proportion of 
progenitors harboring >3 vector copies per cell (from 10 to 65%), compared to β-AS3 HS4 
(<5%) (Figure 2D). 
 
β-AS3 outperforms β-AS3 HS4 in the transduction of long-term repopulating HSCs 
 
We then compared gene transfer efficiency of the β-AS3 HS4 and β-AS3 LVs in long-term 
repopulating SCD HSCs. BM-derived HSPCs from a SCD patient were transduced at an MOI 
of 360 and injected into NSG immunodeficient mice after busulfan-based conditioning (n=5 
mice per vector). As expected, the transduction efficiency of the input SCD HSPC 
populations was higher for β-AS3 than for β-AS3 HS4, as assessed in vitro in BFU-E and 
CFU-GM pools (0.26 and 0.18 β-AS3 HS4 vector copies in BFU-E and CFU-GM; 2.03 and 
0.66 β-AS3 vector copies in BFU-E and CFU-GM). As controls, we transplanted mock-
transduced SCD HSPCs (n=5 mice) and adult G-CSF-mobilized peripheral blood (mPB) or 
cord blood (CB) HSPCs obtained from healthy donors (HD) (n=5 mice). 
Mice were euthanized and hematopoietic organs were analyzed for the engraftment of 
human cells, calculated as percentage of human CD45+ cells in the total human and murine 
CD45+ cell populations. The engraftment was similar among mock and transduced conditions 
in BM, spleen and thymus (Figures 3A). Comparable frequencies were observed upon 
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transplantation of healthy donor HSPCs, except for a higher engraftment of human CD45+ 
cells in the spleen and thymus of mice transplanted with CB-derived HSPCs. We detected a 
similar distribution of B, T and myeloid cells in the CD45+ cell populations across the 
different conditions (Figure S3). 
Total BM cells were isolated and subjected to a CFC assay to assess the gene transfer 
efficiency in HSC-derived BFU-E and CFU-GM pools. Clonogenic potential was similar 
between mock and transduced samples (Figure 3B). The average β-AS3 HS4 VCN per cell 
was 0.04±0.001 in BFU-E and 0.02±0.001 in CFU-GM, whereas the β-AS3-transduced CFCs 
displayed a significantly higher VCN/cell (0.34±0.12 in BFU-E and of 0.23±0.08 in CFU-
GM; Figure 3C).  
Taken together, these results confirmed the superior gene transfer efficiency of the β-AS3 
vector in long-term repopulating HSCs compared to the β-AS3 HS4 LV harboring an 
additional βLCR HS site. 
 
β-AS3 LV-derived transgene expression ameliorates the SCD cell phenotype in vitro 
 
To compare the therapeutic potential of the β-AS3 and β-AS3 HS4 LVs in terms of transgene 
expression and correction of the SCD phenotype, we differentiated in vitro transduced SCD 
BM HSPCs into mature RBCs (n=3-4; 2 donors). Erythroid differentiation was monitored 
over time by flow cytometry and morphological analyses. Downregulation of early erythroid 
markers CD36 and CD71 and upregulation of the late erythroid marker glycophorin A 
(GYPA) occurred similarly in mock and transduced samples (Figure S2A and 2B). RBC 
enucleation was obtained at day-20 post differentiation for all the samples, as demonstrated 
by the loss of cells staining with the nuclear dye DRAQ5 and by morphological analyses 
(Figure S2A, S2B and S2C). 
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HBBAS3 transgene mRNA expression was measured by RT-qPCR in erythroblasts 
derived from β-AS3- and β-AS3 HS4-transduced HSPCs. We observed a strong correlation 
between transgene expression and average VCN for both β-AS3 HS4 and β-AS3 LVs 
(Pearson correlation r=0.99, P<0.0001, Figure 4A). Despite the lack of the HS4 element in 
the β-AS3 construct, no statistically significant differences in HBBAS3 expression were 
observed between the two vectors in erythroblasts derived from HSPCs harboring a similar 
VCN (Figure 4A). Given the higher transduction efficiency, β-AS3 LV-derived HBBAS3 
expression was overall higher in erythroblasts derived from SCD HSPCs transduced at high 
MOIs (e.g. 36 and 360), as compared to β-AS3 HS4-transduced samples (β-AS3 mRNA 
levels: 0.37±0.11 and 0.09±0.03, respectively). Similar results were obtained in BFU-E 
transduced with β-AS3 HS4 and β-AS3 LVs (Figure S4A). 
The expression of the Hb tetramer containing the therapeutic βAS3globin-chain 
(HbAS3) was detected in mature RBCs by HPLC and was accompanied by a reduction in the 
levels of HbS containing βS-chains (Figure 4B and 4C). HbAS3 expression was positively 
correlated with the VCN/cell of β-AS3 HS4 and β-AS3 LVs (Pearson correlation r=0.94, 
P<0.0001 for β-AS3 and r=1, P<0.001 for β-AS3 HS4, Figure 4B). We observed no 
significant differences in HbAS3 content in RBCs derived from HSPCs harboring similar β-
AS3 HS4 and β-AS3 vector copies (Figure 4B and C). Indeed, HbAS3 expression 
normalized per VCN was similar for the 2 vectors (Figure 4B). Notably, HSPC transduction 
with the β-AS3 LV led to greater protein expression at MOIs higher than 36 compared to β-
AS3 HS4 (39.26%±6.92% for β-AS3 and 14.87%±4.09% for β-AS3 HS4; P<0.05). Similarly, 
no differences in HbAS3 expression were observed in BFU-E harboring similar β-AS3 HS4 
and β-AS3 VCNs (Figure S4B). 
The high levels of β-AS3-derived anti-sickling transgene expression prompted us to 
assess the ability of β-AS3 LV to correct the SCD cell phenotype. To measure the frequency 
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of sickling and corrected RBCs, we performed an in vitro sickling assay under hypoxic 
conditions. SCD BM HSPCs were transduced with increasing β-AS3 vector doses and 
differentiated in mature RBCs (n=2 donors). Upon deoxygenation, the frequency of sickling 
RBCs was >80% in mock-transduced samples (Figure 4D). In marked contrast, HSPC 
transduction with the β-AS3 LV led to a decreased frequency of sickling RBCs and to 
significant proportions of biconcave RBCs under 0% O2 (Figure 4D). The percentage of 
corrected (i.e. non-sickling) RBCs increased gradually with the VCN, reaching 34% and 47% 
of corrected RBCs for donor 1 and 2, respectively (Figure 4E). Notably, the extent of the 
RBC correction was positively correlated with the HbAS3 production (Figure 4F).  
 
β-AS3 LV efficiently transduces SCD mobilized HSPCs 
 
We recently showed that HSPCs can be safely and efficiently mobilized from SCD patients 
by using Plerixafor16. To verify if mobilized SCD HSPCs are permissive to β-AS3 LV 
transduction, these cells were transduced at an MOI of 36 and of 360. The average β-AS3 
VCN per cell increased with the vector dose, reaching 1.22 in erythroblasts, 0.97 in BFU-E 
and 1.61 in CFU-GM at the highest MOI (n=1 donor; Figure 5A). Concomitantly, HbAS3 
expression reached 17.97% of total Hb in in vitro generated mature RBCs and 16.18% in 
BFU-E at an MOI of 360 (Figure 5B). 
We next evaluated β-AS3 gene transfer efficiency in long-term repopulating SCD 
mobilized HSCs. Mobilized HSPCs from a SCD patient were transduced at an MOI of 100, 
with a GMP engineering batch of β-AS3 LV, achieving an average VCN of 0.94 and 0.54 
copies in in vitro generated BFU-E and CFU-GM pools. Mock- and β-AS3-transduced cells 
were injected into 3 and 4 NSG mice respectively. At 18 weeks after transplantation, we 
analyzed the engraftment of human hematopoietic cells and average VCN/cell. The 
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engraftment of mock- and β-AS3-transduced cells was not statistically different in BM, 
spleen and thymus (Figure 5C), with no skewing towards a particular lineage in any of the 
samples (Figure S5). Total human cells derived from the mouse BM were then cultured in a 
CFC assay. Mock- and β-AS3-transduced samples gave rise to a similar number of BFU-E 
and CFU-GM with an average VCN of 0.18±0.05 and 0.16±0.05, respectively (Figure 5D 
and 5E).  
Finally, to increase gene transfer efficiency, we transduced healthy donor and SCD 
mobilized HSPCs using a GMP engineering batch of β-AS3, at an MOI of 100 in the 
presence of 16,16-dimethyl-prostaglandin E2 (PGE2).32 PGE2 treatment led to a 2 to 3.6-fold 
increase in VCN/cell, leading to 2.63±1.07 and 1.52±0.33 vector copies in BFU-E and CFU-
GM derived from SCD Plerixafor-mobilized HSPCs (Figure 5F). 
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DISCUSSION 
 
In this study, we describe an advanced design of an anti-sickling HBB expressing 
cassette in the context of an LV vector, to expedite high titer vector production and maximize 
transduction efficiency of human HSPCs while guaranteeing high-level transgene expression 
for potential use in gene therapy for SCD. We compared two LVs containing an HS2+HS3 or 
an HS2+HS3+HS4 mini-βLCR (β-AS3 and β-AS3 HS4), controlling the expression of a 
β
AS3
-globin transgene containing three anti-sickling amino acid substitutions.15 
The β-AS3 LV showed a high transduction efficiency of HSP s from SCD patients, 
leading to a potentially therapeutic production of βAS3-globin chains. Importantly, the high 
transduction efficiency of β-AS3 did not impair erythroid maturation, clonogenic potential 
and in vivo engraftment of transduced HSPCs. A similar LV bearing only HS2 and HS3 
sequences was shown to express therapeutic levels of a wild-type HBB transgene, thus 
correcting a murine model of β-thalassemia as well as human β-thalassemic HSPC-derived 
erythroblasts.17, 18 In line with these studies, preliminary results of a phase I/II gene therapy 
clinical trial treating β-thalassemia with this compact LV are very encouraging.12, 19 However, 
the impact of the HS4 element in HBB-like expressing LVs on transduction efficiency and 
transgene expression has not previously been reported, particularly in the context of SCD. 
Importantly, the correction of SCD requires high expression levels of the therapeutic HBB-
like chain that needs to compete with the endogenous βS-globin for the incorporation into Hb 
tetramers, a situation that does not occur in β-thalassemia. Upon inclusion of a 1.1kb HS4 
element, LV transduction efficiency was severely affected, with a lower proportion of β-AS3 
HS4 vector positive cells and average transgene VCN per transduced cell compared to β-AS3 
LV. In addition, in contrast to β-AS3, increasing doses of β-AS3 HS4 did not improve gene 
transfer efficiency, thereby indicating that the poor performance of the β-AS3-HS4 cannot be 
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overcome by simply increasing MOI. The superior transduction potential of β-AS3 over β-
AS3 HS4 was confirmed in vivo, where differences in gene marking were maintained in 
progenitors derived from long-term repopulating HSCs.  
Premature truncation of the β-AS3 HS4 viral transcript occurred, due to a 
polyadenylation site present within the HS4 element. However, the production of full-length 
viral genomic RNAs was similar for β-AS3 HS4 and β-AS3 vectors, indicating that the 
generation of truncated transcripts is not the main determinant of the low β-AS3 HS4 LV 
titer. The sequence and/or the size of the 1.1-kb HS4 element may impair the production of a 
high-titer and infective LV by affecting the synthesis or the stability of ψ+ viral RNAs in the 
packaging cells. However, the use of a short 304-bp HS4 element restored the  ψ+ viral RNAs 
levels but did not significantly increase the viral titer and infectivity. Therefore, we 
hypothesize that the presence of HS4 sequences (e.g., the core HS4 element) might affect 
other steps of the viral life cycle, such as packaging of the viral RNAs, reverse transcription 
or integration.  
High levels of transgene expression are mandatory for a favorable outcome of gene 
therapy for SCD patients, where globin chain production from the transgene allows the 
displacement of the endogenous βS-globin chain from the hemoglobin tetramers, thus 
ameliorating the sickling RBC phenotype.20 Therefore, it was crucial to confirm that the 
removal of the HS4 element from the mini-LCR does not affect transgene expression, despite 
the beneficial enhancement in gene transfer efficiency. In transgenic mice harboring the 
human HBB locus, deletion of the 280-bp core element of HS4 leads to a severe HBB down-
regulation21, but deletion of the entire HS4 has a mild effect on HBB expression.22 
Interestingly, we show that the HS4 element is dispensable for boosting HBB transgene 
expression in the context of the β-AS3 LV in primary human erythroblasts. Indeed, we 
detected comparable levels of βAS3-globin mRNA and HbAS3 tetramers in erythroid cells 
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derived from samples harboring the same β-AS3 or β-AS3 HS4 average VCN per genome. In 
another HBB-expressing LV, the truncation of the 5’ region of the βLCR HS4 element was 
associated with a higher gene marking in a murine model of β-thalassemia, but lower 
transgene expression levels, as compared to the LV containing the full HS4.23 This 
discrepancy with our study may be ascribed to the potential different activity of HS4 in 
murine and human erythroid cells. Of note, our vector contains a larger HS2 element (~1.5kb 
vs 0.8kb23) that in combination with only HS3 may be sufficient per se to produce high HBB 
transgene expression levels. Importantly, we observed a linear correlation between the vector 
copies and HBB transgene expression for both β-AS3 HS4 and β-AS3 LVs, suggesting that 
HS4 element is dispensable for integration site position-independent transgene expression.  
The remarkable transduction efficiency of SCD HSPCs achieved with β-AS3 
combined with the high βAS3-globin expression levels allowed accumulation of up to 60% 
therapeutic hemoglobin in terminally differentiated RBCs, levels that were never achieved 
with the β-AS3 HS4 LV even at high MOI. A concomitant decrease of HbS tetramers was 
observed, due to the competition of the βAS3-globin chain for incorporation into Hb tetramers, 
likely favored by the presence of the A22 amino acidic residue that increases the affinity of 
the βAS3-globin for HBA.15 The sustained anti-sickling βAS3-globin production (27-47% of 
HBAS3) together with the beneficial reduction of HbS levels were able to inhibit the 
formation of hemoglobin polymers and reduce RBC sickling (34-47% of corrected RBCs), 
proving the efficacy of the β-AS3 LV to reverse the major cellular manifestation of SCD. Of 
note, in compound heterozygotes of SCD and HPFH, a condition characterized by 
maintenance of elevated amounts of anti-sickling fetal HBG polypeptides in adult life, HbF 
levels accounting for as little as 20-30% of the total hemoglobin are associated with the 
absence of SCD symptoms.24 
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Compared to the BB305 vector, which has given encouraging results in β-
thalassaemic patients25 but not consistently in those with SCD,13, 14 β-AS3 differs in two key 
components. First, the mini-HBB in β-AS3 contains three anti-sickling amino acid 
substitutions (G16D, E22A, T87Q) compared to one (T87Q) in BB305,13 giving β-AS3 a 
greater anti-sickling activity. Second, the mini-βLCR in BB305 consists of the HS2, HS3 and 
HS4 elements but is only 2.6kb in length whereas the mini-βLCR in β-AS3, which although 
consists of just the HS2 and HS3 sites, spans 2.7kb. Thus the HS core regions in β-AS3 
possess considerably larger flanking sequences compared to those in BB305. Given that 
distance between the core regions of the βLCR HS sites is crucial for effective mutual 
interaction and chromatin looping leading to βLCR engagement on a downstream promoter 
for efficient transcriptional activation,7 the greater compactness of the βLCR HS sites in 
BB305 could be a disadvantage. 
Studies in SCD patients with mixed donor chimerism following allogeneic 
transplantation indicate that 20% of corrected HSCs are sufficient to reverse the sickle 
phenotype,26-28 in all likelihood due to the increased half-life of corrected over unmodified 
RBCs in vivo. In this regard it is noteworthy that we achieved ~20% of transduced long-term 
repopulating HSCs after transplantation of HSPCs derived from SCD patients either 
harvested from bone marrow or mobilized using Plerixafor.16 Plerixafor-mobilized SCD 
HSPCs represent the only available source of HSCs for a gene therapy approach to SCD, 
since the administration of the conventional mobilizing agent G-CSF in individuals with SCD 
leads to severe adverse events29-31 and the recovery of HSPCs from SCD patients’ BM is 
peculiarly low (M. Cavazzana, unpublished data). Importantly, exposure to PGE2, a known 
molecule that increases gene transfer in long-term repopulating stem cells,32 enhanced 
transduction efficiency in SCD Plerixafor-mobilized HSPCs.  
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In conclusion, in this study we report the functional characterization of a novel and 
efficient LV expressing an anti-sickling HBB transgene in clinically relevant cells from SCD 
patients as part of a program of work aimed at clinical translation of an effective LV-based 
gene therapy approach for SCD. Thus, findings of good transduction and expression 
efficiencies of mobilized HSPCs from SCD patients with the β-AS3 LV bodes well for 
consistent efficacious future clinical application. 
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MATERIALS AND METHODS 
Vector construction 
The expression cassette consisting of DNase I hypersensitive sites HS2 (genomic 
coordinates[hg38]: chr11:5280255-5281665) and HS3 (genomic coordinates[hg38]: 
chr11:5284251-5285452) of the locus control region (βLCR)33 and HBB mini-gene extending 
from -265bp upstream of the transcriptional start site to +300bp downstream of the poly(A)-
addition site (genomic coordinates[hg38]: chr11:5225174-5227336) with a short version of 
intron 2  (genomic coordinates[hg38]: chr11:5203703-5204295),17 was cloned into a pCCL 
lentiviral vector backbone34 to generate the pCCL.β-globin plasmid. The mutations 
determining three anti-sickling amino acid substitutions (G16D, E22A and T87Q)15  were 
introduced in the pCCL.β-globin plasmid by in vitro site-directed mutagenesis to obtain the 
pCCL.β-AS3 plasmid. The addition of the βLCR HS4 element (genomic coordinates[hg38]: 
chr11:5287846-5288936)33 or of the short HS4 fragment (genomic coordinates[hg38]: 
chr11:5288094-5288397) containing  the core HS4 element, to generate the pCCL.β-AS3 
HS4 and the pCCL.β-AS3 HS4 core plasmids, was achieved by replacing the HS2/HS3 
sequence of pCCL.β-AS3 with a commercially synthesized (GeneWiz, South Plainfield, NJ, 
USA) fragment containing a combination of βLCR HS2/HS3/HS4 sites as previously 
described.35 
Lentiviral vector production and titration 
Third-generation lentiviral vectors were produced by calcium phosphate transient transfection 
of HEK293T cells of the transfer vector (pCCL.β-AS3 or pCCL.β-AS3 HS4), the packaging 
plasmid pKLg/p.RRE, the Rev-encoding plasmid pK.REV, and the vesicular stomatitis virus 
glycoprotein G (VSV-G) envelope-encoding plasmid pK.G, as previously described.36 The 
physical titer of vector preparations was measured using the HIV-1 Gag p24 antigen 
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immunocapture assay kit (PerkinElmer, Waltham, MA, USA) and expressed as p24ng/mL. 
The viral infectious titer was calculated by transducing HCT116, K562 and HEL cells. 
HCT116 cells were transduced with serial vector dilutions, as previously described.37 K562 
and HEL cells were transduced overnight with serial dilutions of the virus in DMEM medium 
supplemented of 10% fetal bovine serum (Gibco, Carlsbad, CA, USA), 
penicillin/streptomycin (Gibco, Carlsbad, CA, USA), glutamine (Gibco, Carlsbad, CA, USA) 
and polybrene (8 µg/ml, Sigma-Aldrich, St. Louis, MI, USA). After transduction, cells were 
washed and maintained in complete DMEM medium for one week before determining vector 
copy number (VCN) per genome. VCN was used to calculate the viral infectious titer, 
expressed as transducing units per ml (TU/ml). Viral infectivity was calculated as ratio 
between infectious and physical titers (TU/ng p24).  
Viral transcript quantification 
Total RNA was extracted from HEK293T cells transfected as described above (“Viral vector 
preparation”), using the RNeasy kit (Qiagen, Venlo, Netherlands), which included an in-
column DNase-I treatment step. An additional DNAse treatment was performed after RNA 
purification using the TURBO DNA-free Kit (Ambion, Waltham, MA, USA). Then, RNA 
was reverse-transcribed by extension of random hexamers using the SuperScript III First-
Strand Synthesis kit (Invitrogen, Carlsbad, CA, USA). As negative controls, RNA samples 
were treated without reverse transcriptase (RT). We performed duplex TaqMan RT-qPCR to 
quantify total ψ+ and full-length viral transcripts. GAPDH was used as an internal reference 
standard for RNA normalization.  
Primers and probes used for TaqMan RT-qPCR are listed below: 
HIV1-RNAfullLenght 3 (∆U3) FOR 5’-CAGCTGTAGATCTTAGCCACTTT-3’ 
HIV1-RNAfullLenght (∆U3) REV 5’-AGCAGATCTTGTCTTCGTTGG-3’ 
HIV1-RNAfullLenght (∆U3) PROBE-fam AS 5’-AGTGAATTAGCCCTTCCAGTCCC-3’ 
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HIV1-PSI FOR 5’-CAGGACTCGGCTTGCTGAAG-3' 
HIV1-PSI REV 5’-TCCCCCGCTTAATACTGACG-3’,  
HIV1-PSI PROBE-fam 5’-CGCACGGCAAGAGGCGAGG-3’ 
GAPDH FOR 5’-CTTCATTGACCTCAACTACATGGTTT-3’        
GAPDH REV 5’-TGGGATTTCCATTGATGACAAG-3’                 
GAPDH PROBE-vic 5’-CAAATTCCATGGCACCGTCAAGGC-3’    
Identification of truncated viral transcripts 
Total RNA was extracted from packaging HEK293T cells following transfection for vector 
packaging and reverse-transcribed by using the 3´ RACE Kit (Invitrogen, Carlsbad, CA, 
USA), in accordance with the manufacturer’s instructions. To identify any transcripts with 
pre-mature polyadenylation within the HS4 region, we used a forward primer annealing to 
the HS3 region (HS3 primer 5’-CTCTTACTCATCCCATCACGTATGC-3’) and the UAP 
primer provided in the kit as reverse primer (5’-
CUACUACUACUAGGCCACGCGTCGACTAGTAC-3’). The 3’ RACE PCR product was 
loaded on a 1% agarose gel and the amplicons were visualized by GelRed (Biotium, Fremont, 
CA, USA) staining. After electrophoresis, the amplicons were extracted from the gel, cloned 
using the StrataClone PCR Cloning Kit (Agilent, Santa Clara, CA, USA) and analyzed by 
Sanger sequencing. 
 
HSPC purification and transduction 
We obtained human adult CD34+ HSPCs mobilized with G-CSF from healthy donors. 
Human adult SCD HSPCs were either harvested from bone marrow or mobilized using 
Plerixaflor (NCT 02212535 clinical trial, Necker Hospital, Paris, France). Written informed 
consent was obtained from all subjects. All experiments were performed in accordance with 
the Declaration of Helsinki. The study was approved by the regional investigational review 
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board (reference: DC 2014-2272, CPP Ile-de-France II “Hôpital Necker-Enfants malades”). 
HSPCs were purified by immunomagnetic selection with AutoMACS (Miltenyi Biotec, 
Bergisch Gladbach, Germany) after immunostaining with CD34 MicroBead Kit (Miltenyi 
Biotec, Bergisch Gladbach, Germany).  
CD34+ cells (106 cells/ml) were pre-activated for 24 h in X-VIVO 20 supplemented 
with penicillin/streptomycin (Gibco, Carlsbad, CA, USA) and the following recombinant 
human cytokines (obtained from either CellGenix GmbH, Freiburg, Germany or Peprotech, 
London, UK): 300 ng/ml SCF, 300 ng/ml Flt-3L, 100 ng/ml TPO and 20 ng/ml IL3. After 
pre-activation, cells (106 cells/ml) were transduced for 24 hours in plates coated with 
RetroNectin (10 µg/cm2, Takara Bio, Kusatsu, Japan), in the pre-activation medium 
supplemented with protamine sulfate (4 µg/ml, Sigma-Aldrich, St. Louis, MI, USA or APP 
Pharmaceuticals, Schaumburg, IL, USA). Transductions using 16,16-dimethyl-prostaglandin 
E2 (PGE2; Cayman Chemical) efficacy were performed using conditions previously 
described.13, 32 Multiplicity of infection (MOI) was calculated using the viral infectious titer 
determined in HCT116 cells.  
 
In vitro erythroid differentiation  
A 3-step protocol38 was adapted to generate mature RBCs from mock- and LV-transduced 
CD34+ cells. From days 0 to 6, cells were grown in a basal erythroid medium supplemented 
with the following recombinant human cytokines: 100 ng/mL SCF (Peprotech, London, UK), 
5 ng/mL IL3 (Peprotech, London, UK), and 3 IU/mL of EPO Eprex (Janssen-Cilag, Issy-Les-
Moulineaux, France), and hydrocortisone (Sigma, St. Louis, MI, USA) at 10-6 M. From days 
6 to 9, cells were cultured onto a layer of murine stromal MS-5 cells in basal erythroid 
medium supplemented only with 3 IU/mL EPO Eprex. Finally, from days 9 to 20, cells were 
continued to be cultured on a layer of MS-5 cells in basal erythroid medium but without 
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cytokines. Erythroid differentiation was monitored by May Grunwald-Giemsa staining, flow 
cytometry analysis of the erythroid surface markers CD36 (CD36-V450, BD Horizon, 
Franklin Lakes, NJ, USA), CD71 (CD71-FITC, BD Pharmingen, Franklin Lakes, NJ, USA) 
and GYPA (CD235a-PECY7, BD Pharmingen, Franklin Lakes, NJ, USA). We used the 
nuclear dye DRAQ5 (eBioscience, San Diego, CA, USA) to evaluate the proportion of 
enucleated RBCs. Flow cytometry analyses were performed using the Gallios analyzer and 
Kaluza software (Beckman-Coulter, Brea, CA, USA).  
  
CFC Assay 
The number of hematopoietic progenitors was evaluated by a clonal Colony Forming Cell 
(CFC) assay, where HSPCs were plated at 1x103 cells/ml in methylcellulose-containing 
medium (GFH4435, Stem Cell Technologies, Vancouver, BC, USA) under conditions 
supporting both erythroid and granulo-monocytic differentiation. Numbers of BFU-E and 
CFU-GM colonies were scored after 14 days. BFU-E were randomly picked and collected as 
bulk populations (containing at least 25 colonies) or individual BFU-E to evaluate the 
efficiency of transduction and hemoglobin expression.  
 
Vector copy number analysis 
At day 13 of erythroid differentiation, or 14 days after plating HSPCs in the methylcellulose 
medium, DNA was extracted from transduced cells using the ReliaPrep Blood gDNA 
Miniprep System (Promega, Madison, WI, USA) or the DNA Extract All Reagents Kit 
(ThermoFisher Scientific, Waltham, MA, USA). VCN per diploid genome was determined 
by duplex Taqman quantitative PCR (qPCR) (Applied Biosystems, Foster City, CA, USA), 
as previously described.37 We used primers and probes specific for: (i) the viral ψ (PSI) 
packaging signal (HIV1-PSI FOR 5’-CAGGACTCGGCTTGCTGAAG-3', HIV1-PSI REV 
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5’-TCCCCCGCTTAATACTGACG-3’, HIV1-PSI PROBE 5’-
CGCACGGCAAGAGGCGAGG-3’) and (ii) the human albumin gene (ALB), as an internal 
reference standard (ALB FOR 5’-GCTGTCATCTCTTGTGGGCTGT-3’, ALB REV 5’-
ACTCATGGGAGCTGCTGGTTC-3’, ALB PROBE 5’-
CCTGTCATGCCCACACAAATCTCTCC-3’). Standard curves were obtained by serial 
dilutions of a plasmid containing one copy of ψ and ALB sequences. The number of PSI and 
ALB copies in test samples were extrapolated from the standard curves. 
 
RT-qPCR analysis of globin transcripts 
At day 13 of erythroid differentiation, or 14 days after plating HSPCs in the methylcellulose 
medium, RNA was extracted using RNeasy micro kit (Qiagen, Venlo, Netherlands). Reverse 
transcription of mRNA employed the SuperScript First-Strand Synthesis System for RT-PCR 
(Invitrogen, Carlsbad, CA, USA) with oligo(dT) primers. RT-qPCR was performed using 
SYBR green (Applied Biosystems, Foster City, CA, USA) as a detection system with the 
following primers: 
 
HBBAS3 F: 5’-AAGGGCACCTTTGCCCAG-3’ 
HBBAS3 R: 5’-GCCACCACTTTCTGATAGGCAG-3’ 
HBB F: 5’-AAGGGCACCTTTGCCACA-3’ 
HBB R: 5’-GCCACCACTTTCTGATAGGCAG-3’ 
 
Cation-exchange HPLC analysis of hemoglobin tetramers  
Cation-exchange HPLC analysis was performed using a NexeraX2 SIL-30AC 
chromatograph (Shimadzu, Kyoto, Japan) and the LC Solution software. Hemoglobin 
tetramers from mature RBCs or BFU-E were separated by HPLC using a 2 cation-exchange 
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column (PolyCAT A, PolyLC, Columbia, MD, USA). Samples were eluted with a gradient 
mixture of solution A (20mM bis Tris, 2mM KCN, pH=6.5) and solution B (20mM bis Tris, 
2mM KCN, 250mM NaCl, pH=6.8). The absorbance was measured at 415 nm. 
 
Sickling assay  
RBCs at day-20 of erythroid differentiation, derived from transduced and mock transduced 
SCD HSPCs, were exposed to an oxygen-deprived atmosphere (0% O2) for at least 35 
minutes before image capture, using the AxioObserver Z1 microscope (Zeiss, Oberkochen, 
Germany) and a 20X objective. Images were processed with ImageJ to determine the 
percentage of sickled RBCs per field of acquisition in the total RBC population. 
 
NSG mouse transplantation 
Non-obese diabetic severe combined immunodeficiency gamma (NSG) mice 
(NOD.CgPrkdcscid Il2rgtm1Wj/SzJ, Charles River Laboratories, St Germain sur l’Arbresle, 
France) were housed in a specific pathogen-free facility. Mice at 6 to 8-weeks of age were 
conditioned with busulfan (Sigma, St Louis, MO, US) injected intraperitoneally (25mg/kg 
body weight/day) 24h, 48h and 72h before transplantation. Mock- or LV-transduced CD34+ 
cells (500,000 cells/mouse for SCD BM, HD mPB and HD CB HSPCs and 106 cells/mouse 
for SCD mobilized HSPCs) were transplanted into NSG mice via retro-orbital sinus injection. 
Neomycin and acid water were added in the water bottle. At 10 to 19 weeks post-
transplantation, NSG recipients were sacrificed. Cells were harvested from femur BM, 
thymus and spleen, stained with antibodies against murine or human surface markers (murine 
CD45, BD Biosciences, Franklin Lakes, NJ, USA; human CD45, Miltenyi Biotec, Bergisch 
Gladbach, Germany; human CD3, Miltenyi Biotec, Bergisch Gladbach, Germany; human 
CD14, BD Biosciences, Franklin Lakes, NJ, USA; human CD15, Beckman Coulter, Brea, 
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CA, USA; human CD19, Sony Biotechnologies, San Jose, CA, USA; human CD36, BD 
Biosciences, Franklin Lakes, NJ, USA), and analyzed by flow cytometry using a Gallios 
analyzer and the Kaluza software (Beckman-Coulter, Brea, CA, USA). 100,000 BM cells 
were subjected to the CFC Assay, and BFU-E and CFU-GM pools were analyzed for VCN. 
All experiments and procedures were performed in compliance with the French Ministry of 
Agriculture’s regulations on animal experiments and were approved by the regional Animal 
Care and Use Committee (APAFIS#2101-2015090411495178 v4).  
 
Statistical analyses 
Unpaired t tests were performed to compare vector titer and infectivity, viral genomic RNA 
levels, VCN/cell and the engraftment rate between 2 groups. We used one-way ANOVA test 
when comparing the engraftment rate between >2 groups. We performed Chi-squared test (2-
sample test for equality of proportions with continuity correction) to compare the frequency 
of transduced CFC. Linear regression analyses were performed to assess the correlation 
between VCN/cell and transgene expression. All statistical analyses were performed using 
Prism4 software (GraphPad, La Jolla, CA, USA). The threshold for statistical significance 
was set to P<0.05. 
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FIGURE LEGENDS 
 
Figure 1. Characterization of β-AS3 HBB expressing LVs. (A) Schematic representation 
of β-AS3 HS4 and β-AS3 lentiviral vectors. ∆, deleted HIV-1 U3 region; SD and SA, HIV 
Splicing Donor and Acceptor sites; ψ, HIV-1 packaging signal; RRE, HIV-1 Rev Responsive 
Element; Ex, exons of the human HBB; βp, promoter of HBB; HS2, 3 and 4: DNase I 
hypersensitive site 2, 3 and 4 of human HBB LCR; red arrows indicate the mutations 
introduced in exon 1 (generating amino acid substitutions G16D and E22A) and exon 2 
(generating amino acid substitution T87Q). (B) The histograms show the physical and 
infectious titers and infectivity of β-AS3 HS4 and β-AS3 LVs. Infectious titer and infectivity 
were measured in HTC116 (5 different preparations for each vector) and K562 and HEL 
erythroid cell lines (2 viral preparations per vector). (C) Vector copy number (VCN) in G-
CSF-mobilized CD34+ cells from healthy donors (HD). HSPCs were transduced with 
increasing amounts of three and two preparations of β-AS3 and β-AS3 HS4 LVs, 
respectively. Cells were grown in liquid culture and after one week VCN was determined. A 
linear correlation between β-AS3 vector dose and VCN is obtained, whereas a modest 
increase in VCN was achieved by transducing HSPCs with higher amounts of β-AS3 HS4 
vector preparations. (D) Relative quantification of the ψ+ viral genomic RNA produced by 
HEK293T packaging cells (n=3) by RT-qPCR. The β-AS3 sample was used as a calibrator. 
Data were plotted as mean±SD (unpaired t-test). *, P≤0.05, **, P≤0.01, ****, P≤0.0001, ns, 
not significant. 
 
Figure 2. Gene transfer efficiency in SCD patient-derived BM HSPCs transduced with 
β-AS3 HS4 and β-AS3 LVs. (A) Percentages of CD34+ HSPCs that gave rise to BFU-E and 
CFU-GM in CFC assay. Values shown are mean±SEM of 3 to 5 independent experiments. 
(B) Average VCN/cell in bulk populations of erythroblasts grown in liquid culture, and pools 
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of BFU-E and CFU-GM derived from β-AS3 HS4- and β-AS3-transduced SCD BM HSPCs. 
Values shown are mean±SEM of 2 to 6 independent experiments (n=2 donors). *, P≤0.05 
(unpaired t-test). (C) Percentage of vector+ BFU-E and CFU-GM derived from SCD BM 
HSPCs transduced with β-AS3 HS4. Values shown are mean±SEM of 3 to 6 independent 
experiments (n=2 donors). ***, P≤0.001, ****, P≤0.0001 (chi squared test) (D) Clonal 
analysis of VCN in BFU-E and CFU-GM colonies derived from SCD BM HSPCs transduced 
with β-AS3 HS4 or β-AS3. Values shown are mean±SEM of 3 to 6 independent experiments 
(n=2 donors). A higher proportion of colonies harboring >3 VCN was observed for β-AS3 
LV at MOIs of 36 and 360 (P≤0.001; chi squared test). 
 
Figure 3. β-AS3 HS4 and β-AS3 transduction efficiencies in long-term repopulating 
SCD HSCs. (A) Engraftment of human cells in NSG mice transplanted with mock and LV-
transduced SCD BM CD34+ cells (MOI=360, n=5 mice for each group), and HD mPB (n=3) 
and HD CB (n=2) HSPCs, 15 weeks after transplantation. Engraftment is represented as 
percentage of human CD45+ cells in the total murine and human CD45+ cell population, in 
BM, spleen and thymus. Values shown are mean±SEM. ns, not significant (One-way 
ANOVA test). (B) Human hematopoietic progenitor content in BM mononuclear cells 
(MNC) derived from mice transplanted with either mock- or β-AS3 HS4- and β-AS3-
transduced SCD BM HSPCs. We plotted the percentage of BM MNC giving rise to BFU-E 
and CFU-GM. Values shown are mean±SEM of 4 samples per condition. (C) VCN/cell in 
pools of BFU-E and CFU-GM derived from total BM MNC, obtained from mice injected 
with SCD BM HSPCs transduced with β-AS3 HS4 (n=2 and n=3 for BFU-E and CFU-GM, 
respectively) and β-AS3 (n=3 and n=4 for BFU-E and CFU-GM, respectively) LVs at an 
MOI of 360. Values shown are mean±SEM. *, P≤0.05 (unpaired t-test). 
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Figure 4. Transgene expression in erythroid cells derived from β-AS3 HS4- and β-AS3-
transduced SCD BM HSPCs and phenotypic correction of SCD RBCs by β-AS3. (A) 
HBBAS3 mRNA expression was measured by RT-qPCR in erythroblasts at day-13 post 
induction of erythroid differentiation, normalized using the endogenous βS-globin gene 
(HBBS), and correlated with VCN/cell. The slopes of the linear regression lines for samples 
derived from β-AS3 HS4- and β-AS3-transduced HSPCs were not significantly different 
(P=0.2922). Equations that define the best fit lines were: y= 0.13x – 0.011 (R2=1.0 and 
P<0.0001) for β-AS3 HS4 samples and y= 0.10x – 0.00059 (R2=0.99 and P<0.0001) for β-
AS3 samples. 5 β-AS3 HS4- and 10 β-AS3-transduced samples were analyzed (n=2 donors). 
(B) HbAS3 was quantified by cation-exchange HPLC in RBCs at day 20 of erythroid 
differentiation. The percentage of HbAS3 in the total adult Hb (HbAS3+HbS) was correlated 
with the average VCN/cell. Upper panel: The slopes of the linear regression lines for RBC 
samples derived from β-AS3 HS4- and β-AS3-transduced HSPCs were not significantly 
different (P=0.1446) (line-of-best-fit equation: y= 20.79x – 0.49, R2=0.9905 and P=0.0004 
for β-AS3 HS4 samples and y= 8.08x + 6.10, R2=0.8776 and P<0.0001 for β-AS3 samples). 5 
β-AS3 HS4- and 11 β-AS3-transduced samples were analyzed (n=2 donors). Bottom right 
panel: plot of HbAS3 expression in RBCs derived from β-AS3 HS4- and β-AS3-transduced 
samples harboring a similar VCN/cell. Bottom left panel: HbAS3 expression per VCN/cell. 
Data were plotted as mean±SEM (unpaired t-test). ns, not significant. (C) HPLC 
chromatograms of RBC lysates obtained after 20 days of erythroid differentiation of mock- 
and LV-transduced SCD BM HSPCs. (D-F) In vitro sickling assay measuring the proportion 
of sickled RBC under hypoxic conditions (0% O2). Representative photomicrographs of 
RBCs derived from mock- and β-AS3-transduced samples at 0% of O2 are shown (D; SCD 
donor 1). Scale bars, 20 µm. The percentage of corrected RBCs was correlated to the 
VCN/cell (E) or to HbAS3 expression (F) for 2 SCD donors. The proportion of corrected 
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cells was calculated as the percentage of non-sickled cells in the transduced samples, minus 
the percentage of non-sickled cells in the corresponding mock-transduced sample. Values are 
mean±SEM of 3 and 4 microscopic fields for donor 1 and donor 2, respectively. For donor 2, 
a higher VCN and transgene expression was necessary to achieve a frequency of corrected 
RBCs comparable to the value observed for donor 1. This difference may be due to the 
coinheritance of different genetic disease modifiers along with the SCD mutation. 
 
Figure 5. In vitro and in vivo gene transfer efficiency in cells derived from SCD 
Plerixafor-mobilized β-AS3-transduced HSPCs. (A) VCN/cell in bulk populations of 
erythroblasts, and in pools of BFU-E and CFU-GM derived from β-AS3-transduced SCD 
Plerixafor mobilized HSPCs. Transductions were performed using MOI of 36 and 360. (B) 
HbAS3 expression was quantified by cation-exchange HPLC in BFU-E and RBCs. Average 
VCN/cell is indicated. (C) Engraftment of human CD45+ cells derived from SCD mobilized 
samples in BM, spleen and thymus of NSG mice, 18 weeks after transplantation. Plerixafor-
mobilized SCD HSPCs were transduced with β-AS3 LV at an MOI of 100. Values shown are 
mean±SEM (n=2 and n=4 mice for mock- and β-AS3-transduced samples, respectively). ns, 
not significant (Unpaired t-test). (D) Human hematopoietic progenitor content in BM MNC 
obtained from mice transplanted with mock- or β-AS3-transduced SCD Plerixafor-mobilized 
HSPCs. We plotted the percentage of BM MNC giving rise to BFU-E and CFU-GM. Values 
shown are mean±SEM of 2 and 4 samples obtained from mice receiving mock- and β-AS3-
transduced cells, respectively. (E) Average VCN/cell in pools of BFU-E and CFU-GM 
derived from the BM of mice injected with SCD Plerixafor-mobilized HSPCs transduced 
with β-AS3 (n=4). Values shown are mean±SEM. (F) Average VCN/cell in pools of BFU-E 
and CFU-GM obtained from mobilized HSPCs of a healthy donor (HD mPB) and a SCD 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 36
patient (SCD mPB), transduced with β-AS3 ± PGE2. Values shown are mean±SEM of 
technical replicates. 
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